Literature DB >> 2539504

Survival of athymic (nu/nu) mice after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody.

R S Fujinami1, A Rosenthal, P W Lampert, A Zurbriggen, M Yamada.   

Abstract

Little or no antiviral immune response is mounted in athymic nude mice infected with the Daniels strain of Theiler's murine encephalomyelitis virus. In these athymic mice, increasing levels of infectious virus could be detected in the central nervous system. Seventy-five percent (9 of 12) of the nude mice were moribund or dead by 4 weeks postinfection. In contrast, treatment of Theiler's virus-infected nude mice with a neutralizing monoclonal antibody (H7-2) against the viral protein VP-1 resulted in a dramatic reduction of infectious virus within the central nervous system. All antibody-treated nude animals survived beyond 4 weeks postinfection. Monoclonal antibody titers could be maintained by passive transfer in treated nude mice at levels comparable to those of polyclonal antibody titers found in heterozygous infected nu/+ littermates. Areas of demyelination were detected in the untreated animals as early as 7 days after infection with little or no remyelination present. In approximately one-half of the antibody-treated nude animals, no demyelinating lesions were found. However, the rest of these treated mice were found to have areas of both demyelination and remyelination. Thus, anti-Theiler's murine encephalomyelitis virus antibody against VP-1 can play a dramatic role in the survival of mice, clearance of virus, limiting viral spread, and altering the pattern of disease in the absence of a functional T-cell response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539504      PMCID: PMC250624     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Central nervous system immunity in mice infected with theiler's virus. I. Local neutralizing antibody response.

Authors:  H L Lipton; F Gonzalez-Scarano
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

3.  Mechanism of Theiler's virus-induced demyelination in nude mice.

Authors:  A Rosenthal; R S Fujinami; P W Lampert
Journal:  Lab Invest       Date:  1986-05       Impact factor: 5.662

4.  DA strain of Theiler's murine encephalomyelitis virus induces demyelination in nude mice.

Authors:  R P Roos; R Wollmann
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

5.  A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system.

Authors:  A Zurbriggen; R S Fujinami
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs.

Authors:  R J Clatch; H L Lipton; S D Miller
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

7.  Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TEMV-specific delayed-type hypersensitivity.

Authors:  R J Clatch; R W Melvold; S D Miller; H L Lipton
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

8.  Cellular immunity in chronic Theiler's virus central nervous system infection.

Authors:  S G Rabinowitz; H L Lipton
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

9.  Western and dot immunoblotting analysis of viral antigens and antibodies: application to murine hepatitis virus.

Authors:  P J Talbot; R L Knobler; M J Buchmeier
Journal:  J Immunol Methods       Date:  1984-10-12       Impact factor: 2.303

Review 10.  Experimental models of virus-induced demyelination of the central nervous system.

Authors:  M C Dal Canto; S G Rabinowitz
Journal:  Ann Neurol       Date:  1982-02       Impact factor: 10.422

View more
  35 in total

1.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

2.  Immunization with structural and non-structural proteins of Theiler's murine encephalomyelitis virus alters demyelinating disease.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neurovirol       Date:  2012-03-09       Impact factor: 2.643

3.  Postinfection treatment with antiviral serum results in survival of neural cells productively infected with virulent poliovirus.

Authors:  E A Tolskaya; T A Ivannikova; M S Kolesnikova; S G Drozdov; V I Agol
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  An early, abundant cytotoxic T-lymphocyte response against Theiler's virus is critical for preventing viral persistence.

Authors:  S Dethlefs; M Brahic; E L Larsson-Sciard
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 5.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

6.  Organ-specific protective role of NKT cells in virus-induced inflammatory demyelination and myocarditis depends on mouse strain.

Authors:  Eiichiro Kawai; Fumitaka Sato; Seiichi Omura; Nicholas E Martinez; Pratap C Reddy; Masaru Taniguchi; Ikuo Tsunoda
Journal:  J Neuroimmunol       Date:  2014-11-08       Impact factor: 3.478

7.  Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B.

Authors:  I Tsunoda; Y Wada; J E Libbey; T S Cannon; F G Whitby; R S Fujinami
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

9.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

10.  Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.

Authors:  M K Njenga; K D Pavelko; J Baisch; X Lin; C David; J Leibowitz; M Rodriguez
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.